Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Project description:Experimental screening of a compound library identified a molecule that potently inhibits the growth of the obligate intracellular bacterial pathogen Chlamydia trachomatis in human cells. To identify the molecular target of the compound, three mutant bacterial strains resistant to its inhibitory action were generated by long-term passage in the presence of initially low but increasing concentrations of the molecule. Subsequently, genomic DNA of the three mutant and the wildtype bacteria was isolated and subjected to whole genome sequencing to identify resistance-promoting mutations.
Project description:Multiomics of faecal samples collected from individuals in families with multiple cases of type 1 diabetes mellitus (T1DM) over 3 or 4 months. Metagenomic and metatranscriptomic sequencing and metaproteomics were carried out, as well as whole human genome sequencing. Phenotypic data is available.